Expressing the sense of the House of Representatives that over...
Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.
This bill emphasizes the importance of respecting over 25 years of evidence and numerous peer-reviewed studies that show mifepristone, a medication used in abortion care, is safe and effective. It calls for policies on medication abortion care to be fair, clear, and based on the best scientific research. The bill affects healthcare providers and patients seeking abortion care by advocating for equitable access to medication abortion, which is considered lifesaving and time-sensitive.
As of the latest update, the bill has just been introduced and referred to the House Committee on Energy and Commerce. This means it is in the early stages of the legislative process. Key actions so far include its submission to the House and referral to the relevant committee for further review.
This bill was introduced on May 14, 2026, by Diana DeGette and has several co-sponsors, all of whom are Democrats. It aims to ensure that the policies governing access to abortion medication are grounded in robust scientific evidence and are equitable for all patients.
